A month after regulatory approval of the Sapien XT heart valve in Japan, Edwards Lifesciences (NYSE:EW) said it won reimbursement for the transcatheter aortic valve implant from Japan’s Central Social Insurance Medical Council.
Edwards Lifesciences
TAVI: Edwards wins FDA approval to begin clinical studies of next-gen Sapien 3 valve
Q2 profits surge for Edwards Lifesciences
Edwards Lifesciences (NYSE:EW) posted surging 2nd-quarter profits on modest sales growth, saying sales of its flagship Sapien heart valve reached $90 million for the quarter.
Edwards Lifesciences goes after another set of Medtronic patents
German court rules for Edwards Lifesciences in patent war over Medtronic’s CoreValve heart valve
Edwards Lifesciences wins Japanese approval for next-gen Sapien XT heart valve
Edwards Lifesciences (NYSE:EW) won the green light from Japanese regulators for its Sapien XT transcatheter aortic heart valve system, the 1st device of its kind to hit the shelves in the island-nation.
Edwards Lifesciences’ Perimount heart valve fares well in 25-year study
The Perimount aortic valve implant made by Edwards Lifesciences (NYSE:EW) lasts about 17 years post-implantation, according to 25-year data from a study of the valve in patients younger than 60.
MassDevice.com +7 | The top 7 med-tech stories for the week of June 15, 2013
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Medtronic notches small win in German TAVI war with Edwards Lifesciences
FDA releases full Edwards Lifesciences warning letter
D+Vice Talk – June 7, 2013 with guest speaker Stephen Simpson, medtech analyst
Welcome to the latest edition of the MassDevice.com’s D+Vice Talk, our new webcast, in which we review medical device stories from the last week.